This is the latest episode of the free DDW podcast, “Mass spectrometry and CRISPR are pillars of drug discovery”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How ASMS offers more than seeing what sticks” and “CRISPR screening in the third dimension”.
In the first article, Dr. Zack Gurard-Levin, Chief Scientific Officer at SAMDI Tech, breaks down three critical components to consider to ensure a successful affinity selection mass spectrometry (ASMS) drug discovery programme.
In the second article, Rosie Bryan & Carlos le Sage from Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.
You can also find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
Listen here:
